# Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia

> **NCT00002414** · PHASE2 · UNKNOWN · sponsor: **Centaur Pharmaceuticals** · enrollment: 60 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** CPI-1189

## Key facts

- **NCT ID:** NCT00002414
- **Lead sponsor:** Centaur Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 60 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002414, "Safety and Effectiveness of Giving CPI-1189 to HIV-Infected Patients With AIDS Dementia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00002414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*